Functionalizing Ferritin Nanoparticles for Vaccine Development.
Reads0
Chats0
TLDR
In this paper, a review of the building blocks that enable the formulation of ferritin-based vaccines at an experimental stage, including design, production, and purification are presented.Abstract:
In the last decade, the interest in ferritin-based vaccines has been increasing due to their safety and immunogenicity. Candidates against a wide range of pathogens are now on Phase I clinical trials namely for influenza, Epstein-Barr, and SARS-CoV-2 viruses. Manufacturing challenges related to particle heterogeneity, improper folding of fused antigens, and antigen interference with intersubunit interactions still need to be overcome. In addition, protocols need to be standardized so that the production bioprocess becomes reproducible, allowing ferritin-based therapeutics to become readily available. In this review, the building blocks that enable the formulation of ferritin-based vaccines at an experimental stage, including design, production, and purification are presented. Novel bioengineering strategies of functionalizing ferritin nanoparticles based on modular assembly, allowing the challenges associated with genetic fusion to be circumvented, are discussed. Distinct up/down-stream approaches to produce ferritin-based vaccines and their impact on production yield and vaccine efficacy are compared. Finally, ferritin nanoparticles currently used in vaccine development and clinical trials are summarized.read more
Citations
More filters
Journal ArticleDOI
Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases
TL;DR: The potential of VLP-based vaccine as viable and efficient immunizing agents to induce immunity against virulent infectious agents, including, SARS-CoV-2 and protein nanoparticle-based vaccines has been elaborated and may serve as an effective alternative to conventional vaccine strategies in combating emerging infectious diseases.
Journal ArticleDOI
Engineering Self-Assembling Protein Nanoparticles for Therapeutic Delivery
TL;DR: In this article , the authors provide a brief overview of key designable features of protein nanoparticles and their implications for therapeutic delivery applications, and anticipate that protein nanarticles will rapidly grow in their prevalence and impact as clinically relevant delivery platforms.
Journal ArticleDOI
Potential of Ferritin-Based Platforms for Tumor Immunotherapy
TL;DR: The ferritin-based nanoplatform has great potential for tumor immunotherapy, with greater possibility of clinical transformation, and three barriers (drug loading, modification sites, and animal models) are discussed.
Journal ArticleDOI
Current progress in the development of prophylactic and therapeutic vaccines
TL;DR: In this paper , the development of vaccines in broad fields ranging from conventional prophylactic vaccines against infectious diseases to therapeutic vaccines against chronic diseases and cancer providing a comprehensive overview of recent advances in eight different vaccine forms.
Journal ArticleDOI
Cyclosporine A loaded brain targeting nanoparticle to treat cerebral ischemia/reperfusion injury in mice
Dao-zhou Liu,Qifeng Ji,Ying Cheng,Miao Liu,Bang-Le Zhang,Qibing Mei,Menglei Huan,Si-yuan Zhou +7 more
TL;DR: In this article , a cerebral infarction tissue targeted nanoparticle (CsA@HFn) was developed to treat cerebral ischemia/reperfusion injury, which is one of the main causes of death and disability in the world.
References
More filters
Posted ContentDOI
SARS-CoV-2 Ferritin Nanoparticle Vaccines Elicit Broad SARS Coronavirus Immunogenicity
Michael Gordon Joyce,Wei-Hung Chen,Rajeshwer S. Sankhala,Agnes Hajduczki,Paul V. Thomas,Misook Choe,Elizabeth J. Martinez,William C. Chang,Caroline E. Peterson,Elaine B. Morrison,Clayton Smith,Rita E. Chen,Aslaa Ahmed,Lindsay Wieczorek,Alexander R. A. Anderson,James Brett Case,Yifan Li,Therese Oertel,Lorean Rosado,Akshaya Ganesh,Connor Whalen,Joshua M. Carmen,Letzibeth Mendez-Rivera,Christopher P. Karch,Neelakshi Gohain,Zuzana Villar,David McCurdy,Zoltan Beck,Jiae Kim,Shikha Shrivastava,Ousman Jobe,Dussupt,Sebastian Molnar,Ursula Tran,Chandrika B. Kannadka,Sandrine Soman,Caitlin Kuklis,Michelle Zemil,Htet Khanh,Weimin Wu,Matthew A. Cole,Debra K. Duso,Larry W. Kummer,Tricia J. Lang,Shania E. Muncil,Currier,Shelly J. Krebs,Victoria R. Polonis,Saravanan Rajan,Patrick M. McTamney,Mark T. Esser,William W. Reiley,Morgane Rolland,Val Nd,Michael S. Diamond,Gregory D. Gromowski,Gary R. Matyas,Mangala Rao,Nelson L. Michael,Kayvon Modjarrad +59 more
Journal ArticleDOI
Probing bulky ligand entry in engineered archaeal ferritins.
Lorenzo Calisti,Irene Benni,Matilde Cardoso Trabuco,Paola Baiocco,Barbara Ruzicka,Alberto Boffi,Elisabetta Falvo,Francesco Malatesta,Alessandra Bonamore +8 more
TL;DR: The data obtained indicate clearly that the protein matrix in archaea ferritins does not provide a significant barrier against bulky, negatively charged ligands such as DTNB, a finding of relevance in view of the multiple biotechnological applications of these ferritin mutants that envisage ligand encapsulation within the internal cavity.
Journal ArticleDOI
A ferritin nanoparticle vaccine for foot-and-mouth disease virus elicited partial protection in mice
TL;DR: The partial survival provided by the ferritin nanoparticle vaccines indicated that further study of the effects of the fused ferritIn nanoparticle FMDV vaccines in animals is warranted.
Journal ArticleDOI
Application of crossflow ultrafiltration for scaling up the purification of a recombinant ferritin.
TL;DR: A highly efficient, large scale purification protocol mainly based on crossflow ultrafiltration, starting from fermented bacterial paste, that can easily remove contaminant proteins as well as DNA molecules in the absence of expensive and time consuming chromatographic steps is presented.
Journal ArticleDOI
An Apoferritin-Hemagglutinin Conjugate Vaccine with Encapsulated Nucleoprotein Antigen Peptide from Influenza Virus Confers Enhanced Cross Protection.
TL;DR: HA.AFt+NP conjugate vaccine, therefore, may represent a new strategy for developing a potential universal influenza vaccine without need of any adjuvant, and further broaden the application of AFt nanocages in the areas of vaccine development and delivery system.